A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1010 in Healthy Adults
Completed · Phase 2 · NCT05606965
Conditions: Influenza
At a glance
- Research payments reported, 2025
- $725,914
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 172
About the trial
- Sponsor
- ModernaTX, Inc.
- Tested
- mRNA-1010 (biological), Egg-based Quadrivalent Influenza Vaccine (biological), Adjuvanted Quadrivalent Influenza Vaccine (biological), Inactivated Influenza Vaccine (biological), mRNA-1345 (biological), mRNA-1045 (biological)
- Dates
- Started 2022-11-02; completion 2025-11-13
- Results posted
- Not yet
The main purpose of the study is to evaluate the safety, reactogenicity, and the humoral immunogenicity of mRNA-1010 and comparator influenza vaccines against homologous influenza A and B strains at Day 29.
From ClinicalTrials.gov, last updated 2025-11-24. Full record, eligibility and contacts (opens in a new tab)
Industry funding
ModernaTX, Inc. reported $725,914 in research payments for this study in 2025 (36 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Washington University $725,914
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.